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Aims Recent observations in chronic stable heart failure suggest that high-dose loop diuretics (HDLDs) have detrimental
prognostic effects in patients with high blood urea nitrogen (BUN), but recent findings have also indicated that diure-
tics may improve renal function. Carbohydrate antigen 125 (CA125) has been shown to be a surrogate of systemic
congestion. We sought to explore whether BUN and CA125 modulate the mortality risk associated with HDLDs
following a hospitalization for acute heart failure (AHF).
Methods
and results
We analysed 1389 consecutive patients discharged for AHF. CA125 and BUN were measured at a mean of 72+ 12 h
after admission. HDLDs (≥120 mg/day in furosemide equivalent dose) were interacted to a four-level variable
according to CA125 (.35 U/mL) and BUN (above the median), and related to all-cause mortality. At a median
follow-up of 21 months, 561 (40.4%) patients died. The use of HDLDs was independently associated with increased
mortality [hazard ratio (HR) 1.23, 95% confidence interval (CI) 1.01–1.50], but this association was not homoge-
neous across CA125–BUN categories (P for interaction ,0.001). In patients with normal CA125, use of HDLDs
was associated with high mortality if BUN was above the median (HR 2.29, 95% 1.51–3.46), but not in those
with BUN below the median (HR 1.22, 95% CI 0.73–2.04). Conversely, in patients with high CA125, HDLDs
showed an association with increased survival if BUN was above the median (HR 0.73, 95% CI 0.55–0.98) but
was associated with increased mortality in those with BUN below the median (HR 1.94, 95% CI 1.36–2.76).
Conclusion The risk associated with HDLDs in patients after hospitalization for AHF was dependent on the levels of BUN and
CA125. The information provided by these two biomarkers may be helpful in tailoring the dose of loop diuretics at
discharge for AHF.
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Introduction
Loop diuretics are nearly universally used for relieving symptoms
of systemic congestion in patients with heart failure (HF), especially
during episodes of clinical decompensation.1,2 Paradoxically, a
number of studies326 have reported an increased risk for
adverse outcomes associated with higher doses of loop diuretic
treatment. Furthermore, the optimal use of loop diuretics
remains a real clinical challenge, and their dose titration is largely
intuitive.
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Blood urea nitrogen (BUN) is a well-known marker of renal
function, and hence its serum concentrations vary according to
changes in glomerular filtration rate (GFR). Recent studies729
have also shown that BUN correlates with neurohormonal activa-
tion parameters. Testani et al.9 reported a significant interaction
between high-dose loop diuretics (HDLDs) and BUN in a selected
cohort of 2456 compensated HF patients with left ventricular ejec-
tion fraction (LVEF) ≤ 35%. These authors found that the risk
associated with HDLD use was strongly dependent on BUN
concentrations, with reduced survival when BUN was above
the median.
On the other hand, recent studies10–13 have also highlighted
the importance of venous congestion in the pathophysiology
of renal dysfunction in HF. For instance, a recent study by
Damman et al.13 suggested that furosemide may prevent
tubular renal injury in a small group of patients with HF. Never-
theless, it is recognized that the accuracy of symptoms and signs
for quantifying systemic congestion in HF is limited.14 In this
regard, various studies15218 have suggested that the serum
tumour marker carbohydrate antigen 125 (CA125) may be a re-
liable surrogate for systemic congestion, and associated with
adverse outcomes in acute and chronic HF. Thus, we hypothesize
that the prognostic effect of HDLDs is modulated by the balance
between the beneficial decongestion vs. the negative neurohor-
monal effect.
We sought to explore, in a cohort of patients hospitalized with
acute heart failure (AHF), the relationship between discharge
HDLD and all-cause mortality, and whether the association is
modulated by surrogate markers of systemic congestion (CA125)
and renal dysfunction/neurohormonal activation (BUN).
Methods
Study group and protocol
We prospectively studied a cohort of 1538 patients consecutively ad-
mitted to the cardiology department from a tertiary hospital (Hospital
Clı´nico Universitario de Valencia) with the diagnosis of AHF. AHF was
defined according to current guidelines.1,2,19 Patients were followed-up
from hospital discharge occurring between 1 January 2004 and 9
March 2011. By design, patients who died (n ¼ 80) or received a
heart valve replacement during the index hospitalization were
excluded (n ¼ 69), leaving 1389 patients as the study sample. In add-
ition, patients with a final diagnosis of acute coronary syndrome,
active sepsis/pneumonia, terminal cancer, or end-stage renal disease
on dialysis were excluded from the study. Demographic information,
medical history, vital signs, 12-lead electrocardiogram, and laboratory
and drug utilization data were routinely determined on admission
and throughout the hospital course, using pre-established registry
questionnaires. All patients received intravenous treatment with fur-
osemide for at least the first 48 h. LVEF was assessed with echo
(Agilent Sonos 5500-Phillips) during the index hospitalization. Treat-
ment with angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, beta-blockers, aldosterone antagonists, anticoagu-
lants, diuretics, and other therapeutic strategies were individualized fol-
lowing established guidelines operating at the time the patient was
recruited in the registry.1,2,19
Outcomes
Patients were followed-up until death, lost to follow-up, valve replace-
ment, or cardiac transplantation. All-cause mortality was selected as
the main endpoint, and cardiovascular (CV) mortality as a secondary
endpoint. The information regarding the cause of death was extracted
from the patients’ clinical chart, and adjudicated by an investigator who
was blinded to the hypothesis of the study. Deaths related to CV aeti-
ology included sudden death, progressive HF death, and other
CV-related deaths. Moreover, those patients who died outside the
hospital (n ¼ 157), in which the circumstances concerning the death
were unknown, were assumed to be CV in origin for the purpose of
analysis. This study conforms to the principles outlined in the Declar-
ation of Helsinki and was approved by an institutional review commit-
tee. All patients gave informed consent.
Blood urea nitrogen and carbohydrate
antigen 125 measurements
Blood urea nitrogen and serum CA125 were obtained simultaneously
during patients’ hospitalization (at a mean of 72+ 12 h after admis-
sion). CA125 was measured using commercially available immunoassay
kits (Elecsys CA125 II assay-Roche Diagnostics) and BUN was mea-
sured using a kinetic test with urease (Roche-Hitachi systems
cobas c). A derived variable was constructed dichotomizing BUN by
its median (, 24.8 mg/dL or ≥ 24.8 mg/dL) and serum CA125 by its
upper limit of normality (,35 U/mL or ≥ 35 U/mL). Hence, the
study sample was stratified on the following four categories: C1
(n ¼ 239), with low CA125 and high BUN; C2 (n ¼ 269), with low
CA125 and low BUN; C3 (n ¼ 437), with high CA125 and low
BUN; and C4 (n ¼ 444), with high CA125 and high BUN.
Loop diuretic treatment
Overall, patients’ treatment decisions were left at the discretion of the
cardiologist in charge of the patient. No specific recommendations
regarding prescription of diuretics were followed according to the
levels of any marker. All patients were discharged on diuretics
(furosemide ¼ 69.1%, torasemide ¼ 24.9%, furosemide + hydrochlor-
othiazide (HCTZ) ¼ 4.2%, torasemide + HCTZ ¼ 1.44%, and HCTZ
alone ¼ 0.36%). Total loop diuretic dose (mg/day) was converted to
furosemide equivalent dose (FED) following the equation used by
Levy et al.20 The conversion used was furosemide 80 mg ¼ torasemide
40 mg ¼ HCTZ 25 mg. HCTZ contributed only when added to loop
diuretics. Thus, five patients were included in the analysis with
FED ¼ 0. For the association with mortality risk, FED was explored
as continuous and dichotomized according to a pre-specified cut-off
point used to define HDLD ( ≥ 120 mg/day).
Statistical analysis
Continuous variables with and without symmetrical distributions were
expressed as mean +SD and median [interquartile range (IQR)], re-
spectively. For their comparison, Student’s t-test, analysis of variance
(ANOVA), or Kruskal–Wallis rank test was used as appropriate. Dis-
crete variables were presented as percentages and compared with x2
test. HDLD mortality rates were depicted among BUN–CA125 cat-
egories using the Kaplan–Meier method, and their differences tested
by the Peto–Peto Prentice test. As a pre-specified hypothesis, we in-
tentionally tested for homogeneity of the effect of continuous and
dichotomized FED (into HDLD ≥120 mg/day) on mortality among
the CA125–BUN categories. Multivariable analysis for all-cause mor-
tality was performed by using a flexible parametric survival analysis
described by Royston et al.21 Baseline hazard function was modelled
with three degrees of freedom (df) restrictive cubic splines (RCS).
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Candidate covariates for the initial multivariable model were chosen
based on previous medical knowledge, and regardless of their
P-value. Then, a reduced, although highly predictive model, was
derived by backward elimination using a ‘multivariable fractional poly-
nomial’ algorithm.22The final model included as covariates age, gender,
obesity, prior admission for AHF, last known New York Heart Associ-
ation (NYHA) class before admission (under stable conditions), hyper-
tension, diabetes mellitus, history of myocardial infarction, dementia,
systolic blood pressure, LVEF ,50%, heart rate, atrial fibrillation,
serum creatinine, hyponatraemia (sodium ,135 mEq/L), anaemia
(haemoglobin ≤ 12 g/L for women and ≤ 13 g/L for men), brain natri-
uretic peptide, high sensitivity C-reactive protein, and treatment with
beta-blockers, oral anticoagulants, statins, and mineralcorticoid recep-
tor inhibitors. For CV mortality, a multivariable competing risks
analysis23 was used, and the estimates are presented as the subdistri-
bution hazard rate (SHR) with 95% confidence intervals (CIs). The
CV mortality final model included a similar set of covariates to that
of the main model. The proportionality assumption for the hazard
function over time was tested by interacting the variables retained in
the final model with time. Anaemia, use of angiotensin-converting
enzyme inhibitors, and hypertension were included in the final
models with time-dependent effects. HDLD mortality rates [expressed
as per 10 person-years (PYs)] were estimated from the multivariable
regression model. The performance of the survival models was
assessed by the Harrell’s C-statistic. A two-sided P-value of ,0.05
was considered to be statistically significant for all analyses. All analyses
were performed using Stata 12 (StataCorp, 2011, Stata Statistical Soft-
ware: Release 12. College Station, TX, USA).
Results
The mean age in our sample was 72.7+ 11.5 years; 51% were
female, 46.6% exhibited LVEF .50%, 37.9% had prior history of
ischaemic heart disease, and median length of stay was 7 days
(5–11). The medians (IQR) for FED, BUN, and serum CA125
were 80 (40–100) mg/day, 24.8 (19.2–33.6) mg/dL, and 54 (24–
125) U/mL, respectively. All-cause mortality rates are depicted
through Kaplan–Meier curves in Supplementary material, Figure
S1. Overall, CA125 and BUN markers identified four subpopula-
tions that differ in most of the indicators of disease severity
(Table 1). Indeed, patients in C1 and C4 showed the worst baseline
risk profile, including higher dose of HDLDs (24% and 33%, re-
spectively, as compared with 17% and 21% for C2 and C3) and
the higher mortality risk (Supplementary material, Figure S1). More-
over, patients receiving HDLDs (24.4% of our population) were
shown to be sicker and exhibited higher mortality rates
(Table 2). The adjusted interaction between CA125 (.35 U/
mL/ ≤ 35 U/mL) and BUN (above/below the median) was not sig-
nificant (P ¼ 0.930), indicating that the prognostic value of high
CA125 did not differ substantially according to BUN status.
Loop diuretics and mortality
At a median follow-up of 1.72 years (IQR ¼ 0.61–3.55), 561
(40.4%) patients died. Of these 561 deaths, 404 (72%) were docu-
mented as being CV-related deaths. As regards the entire popula-
tion, HDLD was independently associated with all-cause mortality
(HR 1.23, 95% CI 1.01–1.50; P ¼ 0.04). As a main effect, continu-
ous FED (transformed as FEDsqrt) was positively associated with
mortality, although such an association did not achieve statistical
significance (HR 1.03, 95% CI 0.99–1.06, P ¼ 0.16).
Furosemide equivalent dose and all-cause
mortality across carbohydrate antigen
125–blood urea nitrogen categories
Continuous FED was tested against mortality with a df(4) RCS, and
interacting with CA125–BUN categories (P for interaction ¼
0.0034). The P-value for linearity supports the lack of linearity in
the risk function for FED (P ¼ 0.001). Figure 1 shows a differential
adjusted risk between the continuum of FED and mortality across
CA125–BUN categories, in terms of HR, with the value of FED
40 mg/day used as reference. As FED increased above 40 mg/day,
the HR for mortality increased in C1 (low CA125/high BUN)
and C3 (high CA125/low BUN) categories (Figure 1A and C, re-
spectively). In C2 (low CA125/low BUN), increases in FED trans-
lated into a neutral effect on mortality (Figure 1B). However,
increases in FED for patients in C4 (high CA125/high BUN)
were associated with marginal survival benefit (Figure 1D).
The analysis dichotomizing FED into HDLD ( ≥ 120 mg/day)
also revealed a significant interaction with CA125–BUN categories
(P for interaction ,0.001). The corresponding adjusted estimates
are presented in Table 3. HDLDs were associated with an
increased risk of mortality in patients with low CA125 and BUN
above the median (C1), but not in those below the median
(C2). Conversely, in patients with high CA125, the administration
of HDLDs showed a survival benefit only if BUN was above the
median (C4); for those with BUN below the median, it became
a significant risk factor for mortality.
In order to understand the disease course and the potential
basis for the above HRs, we estimated the baseline hazard function
among those patients with and without HDLD and plotted against
follow-up time. Figure 2 shows the adjusted mortality rates
(expressed as per 10 PYs) at each BUN–CA125 category. The
highest death rates correspond to patients on HDLDs which
belong to groups C1 and C3 (10 deaths per 10 PYs, approximate-
ly) (Figure 2A and C). For patients in C2, death rates among those
on HDLDs were similar (Figure 2B). For C4 (Figure 2D), death rates
were higher for those on HDLDs ¼ 0 (8.5 deaths per 10 PYs, ap-
proximately) compared with those taking HDLDs (6 deaths per 10
PYs). These figures are also telling us that overall, the death rate
seems to be highest  1 year after discharge, and it decreases
after that time to plateau at 4 years.
Furosemide equivalent dose and
cardiovascular mortality across
carbohydrate antigen 125–blood urea
nitrogen categories
High-dose loop diuretics also proved to be independently asso-
ciated with CV mortality, with an effect that varied according to
BUN–CA125 categories. The direction and strength of the associ-
ation are similar to those of all-cause mortality (Table 3).
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Table 1 Baseline characteristics of the population stratified by carbohydrate antigen 125 and blood urea nitrogen status
Variables C1 (n5 239) C2 (n5 269) C3 (n 5 437) C4 (n5 444) Omnibus P-value
Demographic and medical history
Age, years 76+9 70+12 69+13 76+9 ,0.001
Male, n (%) 109 (45.6) 117 (43.5) 229 (52.4) 225 (50.7) 0.076
Previous admission for AHF, n (%) 142 (59.4) 181 (67.3) 321 (73.5) 267 (60.1) ,0.001
LOS, daysa 7 (5–10) 7 (5–9) 7 (5–11) 8 (6–12.5) 0.001
Hypertension, n (%) 215 (90) 214 (79.6) 302 (69.1) 358 (80.6) ,0.001
Diabetes mellitus, n (%) 98 (41.0) 105 (39.0) 165 (37.8) 211 (47.5) 0.020
Dyslipidaemia, n (%) 119 (49.8) 130 (48.3) 162 (37.1) 221 (49.8) ,0.001
Current smoker, n (%) 12 (5.0) 40 (14.9) 62 (14.2) 50 (11.3) 0.001
Previous smoker, n (%) 51 (21.3) 47 (17.5) 95 (21.7) 93 (20.9) 0.558
Ischaemic heart disease, n (%) 100 (41.8) 91 (33.8) 145 (33.2) 191 (43) 0.006
Valvular heart disease, n (%) 52 (21.8) 60 (22.3) 109 (24.9) 114 (25.7) 0.580
ADHF, n (%) 142 (59.4) 156 (58) 336 (76.9) 327 (73.6) ,0.001
Acute pulmonary oedema, n (%) 61 (25.5) 78 (29.0) 68 (15.6) 84 (18.9) ,0.001
Hypertensive AHF, n (%) 32 (13.4) 34 (12.6) 31 (7.1) 22 (5.0) ,0.001
NYHA class III/IV, n (%)b 51 (21.3) 33 (12.3) 67 (15.3) 102 (23.0) 0.001
Previous HF, n (%) 81 (33.9) 82 (30.5) 106 (24.3) 155 (34.9) 0.004
Previous MI, n (%) 70 (29.3) 62 (23) 98 (22.4) 142 (32.0) 0.005
COPD, n (%) 56 (23.4) 54 (20.1) 83 (19) 103 (23.2) 0.358
PAD, n (%) 30 (12.6) 16 (5.9) 28 (6.4) 37 (8.3) 0.020
Stroke, n (%) 25 (10.5) 18 (6.7) 39 (8.9) 56 (12.6) 0.063
Renal failure, n (%) 72 (30.1) 11 (4.1) 18 (4.1) 126 (28.4) ,0.001
Radiological pleural effusion, n (%) 57 (23.8) 64 (23.8) 243 (55.6) 253 (57) ,0.001
Peripheral oedema, n (%) 105 (43.9) 123 (45.7) 270 (61.8) 297 (66.9) ,0.001
Previous use of diuretics, n (%) 150 (62.8) 149 (55.4) 209 (47.8) 321 (72.3) ,0.001
Previous use of beta-blockers, n (%) 63 (26.4) 67 (24.9) 98 (22.4) 125 (28.2) 0.265
Previous use of ACEIs, n (%) 126 (52.7) 130 (48.3) 153 (35) 211 (47.5) ,0.001
Previous use of ARBs, n (%) 10 (4.2) 10 (3.7) 17 (3.9) 11 (2.5) 0.582
Previous use of statins, n (%) 84 (35.1) 92 (34.2) 115 (26.3) 151 (34) 0.029
Vital signs
Heart rate, b.p.m. 98+28 105+31 105+29 99+30 0.001
SBP, mmHg 155+39 159+38 150+34 145+34 ,0.001
DBP, mmHg 83+21 87+22 85+19 79+19 ,0.001
Electrocardiogram
Atrial fibrillation, n (%) 85 (35.6) 106 (39.4) 203 (46.5) 209 (47.1) 0.008
QRS .120 ms, n (%) 77 (32.2) 87 (32.3) 113 (25.9) 145 (32.7) 0.103
Laboratory
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Table1 Continued
Variables C1 (n5 239) C2 (n5 269) C3 (n 5 437) C4 (n5 444) Omnibus P-value
Serum creatinine, mg/dL 1.55+0.73 1.02+0.26 1.02+0.31 1.55+0.65 ,0.001
BUN, mg/dL 38.5+15 19.2+3.6 18.8+3.9 37.7+13.1 ,0.001
Uric acid, mg/dL 8.5+2.3 7.0+2 7.2+2 8.7+2.5 ,0.001
Sodium, meq/L 139.3+3.6 139.4+4.7 138.7+4.6 138.9+4.8 0.145
Troponin I, ng/mLa 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0.001
Troponin I .0.2 ng/mL, n (%) 68 (28.5) 60 (22.3) 67 (15.3) 107 (24.1) ,0.001
BNP, pg/mLa 128 (70–226) 110 (72–176) 156 (94–270) 208 (101–378) ,0.001
Relative lymphocyte count, % 19+11 20+11 18+10 17+11 0.008
CA125, U/mLa 19 (13–27) 19 (14–25) 102 (62–183) 97 (56–169) ,0.001
Total cholesterol, mg/dL 176.3+43.2 182.8+42.3 167+44.5 160.4+43.3 ,0.001
Triglycerides, mg/dL 137.1+71.7 127+59.2 107.8+50.3 118.3+53 ,0.001
Echocardiography
LVEF, % 53.2+14.3 52.2+15.5 48.4+15.8 49.3+15.5 ,0.001
LVEF ≤50%, n (%) 88 (36.8) 109 (40.5) 220 (50.3) 230 (51.8) ,0.001
LAD, mm 41.3+7.6 42.2+7.2 44.2+8 43.8+7.7 ,0.001
LVDD, mm 54.9+9 55.2+9.9 56.2+9.9 55.8+9.7 0.307
Medical treatment
Beta-blockers, n (%) 136 (56.9) 152 (56.5) 270 (61.8) 238 (53.6) 0.104
Diuretics, n (%) 239 (100) 269 (100) 437 (100) 444 (100) 1.00
HDLDs, n (%) 58 (24.3) 45 (16.7) 90 (20.6) 146 (32.9) ,0.001
Furosemide equivalent dose, mg/daya 80 (40–80) 80 (40–80) 80 (40–80) 80 (40–120) ,0.001
Mineralcorticoid receptor inhibitors, n (%) 39 (16.3) 56 (20.8) 144 (33) 83 (18.7) ,0.001
ACEIs, n (%) 86 (36) 119 (44.2) 190 (43.5) 152 (34.2) 0.008
ARBs, n (%) 76 (31.8) 92 (34.2) 123 (28.1) 143 (32.2) 0.351
Oral anticoagulants, n (%) 86 (36) 106 (39.4) 188 (43) 183 (41.2) 0.334
Nitrates, n (%) 56 (23.4) 40 (14.9) 60 (13.7) 107 (24.1) ,0.001
Digoxin, n (%) 46 (19.2) 64 (23.8) 129 (29.5) 105 (23.6) 0.022
Outcomes
All-cause mortality, n (%) 102 (42.7) 79 (29.4) 141 (32.3) 239 (53.8) ,0.001
Cardiovascular mortality, n (%) 75 (31.4) 50 (18.6) 97 (22.2) 182 (41.0) ,0.001
Follow-up time, yearsa 1.5 (0.7–3.4) 2.1 (0.9–4.2) 2.0 (0.6–3.9) 1.4 (0.5–3.0) ,0.001
Values are expressed as mean+ SD, unless otherwise specified; categorical variables are presented as percentages.
CA125 and BUN categories: C1, CA125 ≤35 U/mlL and BUN above the median; C2, CA125 ≤35 U/mL and BUN below the median; C3, CA125 .35 U/mL and BUN below the median; C4, CA125 .35 U/mL and BUN above the median.
ACEI, angiotensin-converting enzyme inhibitor; ADHF, acute decompensated heart failure; AHF, acute heart failure; ARB, angiotensin II receptor blocker; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CA125, carbohydrate antigen
125; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HDLD, high-dose loop diuretic; HF, heart failure; LAD, left atrial diameter; LOS, length of stay; LVDD, left ventricular diastolic diameter; LVEF, left ventricular
ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PAD, peripheral artery disease; SBP, systolic blood pressure.
aValue presented as the median (interquartile range).
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Table 2 Baseline characteristics of the population according to furosemide equivalent dose at discharge
Variables Furosemide equivalent dose <120 mg/day
(n 5 1050)
Furosemide equivalent dose ≥120 mg/day
(n5 339)
P-value
Demographic and medical history
Age, years 72+12 74+11 0.029
Male, n (%) 510 (48.6) 170 (50.1) 0.618
Previous admission for AHF, n (%) 746 (71) 165 (48.7) ,0.001
Hypertension, n (%) 812 (77.3) 277 (81.7) 0.095
Diabetes mellitus, n (%) 408 (38.9) 171 (50.4) ,0.001
Dyslipidaemia, n (%) 469 (44.7) 163 (48.1) 0.286
Current smoker, n (%) 129 (12.3) 35 (10.3) 0.384
Previous smoker, n (%) 216 (20.6) 70 (20.6) 1.000
Ischaemic heart disease, n (%) 378 (36) 149 (44) 0.010
Valvular heart disease, n (%) 238 (22.7) 97 (28.6) 0.029
ADHF, n (%) 714 (68) 247 (72.9) 0.104
Acute pulmonary oedema, n (%) 225 (21.4) 66 (19.5) 0.490
Hypertensive AHF, n (%) 98 (9.3) 21 (6.2) 0.075
Previous HF, n (%) 265 (25.2) 159 (46.9) ,0.001
Previous MI, n (%) 256 (24.4) 116 (34.2) 0.001
COPD, n (%) 222 (21.1) 74 (21.8) 0.819
PAD, n (%) 76 (7.2) 35 (10.3) 0.083
Stroke, n (%) 105 (10) 33 (9.7) 1.000
Renal failure, n (%) 145 (13.8) 82 (24.2) ,0.001
Radiological pleural effusion, n (%) 423 (40.3) 194 (57.2) ,0.001
Peripheral oedema, n (%) 568 (54.1) 227 (67) ,0.001
Previous use of diuretics, n (%) 559 (53.2) 270 (79.6) ,0.001
Previous use of beta-blockers, n (%) 270 (25.7) 83 (24.5) 0.668
Previous use of ACEI, n (%) 451 (43) 169 (49.9) 0.028
Previous use of ARB, n (%) 37 (3.5) 11 (3.2) 1.000
Previous use of statins, n (%) 334 (31.8) 108 (31.9) 1.000
Vital signs
Heart rate, b.p.m. 104+31 97+25 ,0.001
SBP, mmHg 153+36 145+36 0.001
DBP, mmHg 85+21 78+18 ,0.001
Electrocardiogram
Atrial fibrillation, n (%) 452 (43) 151 (44.5) 0.659
QRS .120 ms, n (%) 311 (29.6) 111 (32.7) 0.278
Laboratory
Haemoglobin, g/dL 12.7+1.9 12.4+1.8 0.005
Serum creatinine, mg/dL 1.23+0.53 1.45+0.68 ,0.001
BUN, mg/dL 27.1+12.8 32+16.1 ,0.001
Uric acid, mg/dL 7.7+2.3 8.3+2.6 ,0.001
Sodium, meq/L 139.1+4.5 138.7+4.8 0.133
Troponin I, ng/mLa 0 (0–0.1) 0 (0–0.06) 0.083
Troponin I .0.2 ng/mL, n (%) 230 (21.9) 72 (21.2) 0.821
BNP, pg/mLa 140 (84–252) 195 (98–356) ,0.001
Relative lymphocyte count, % 19+11 17+9 0.001
CA125, U/mLa 51 (24–113) 70 (29–165) ,0.001
Total cholesterol, mg/dL 172.2+44 161.5+44 ,0.001
Triglycerides, mg/dL 121.6+58.4 114.6+56.3 0.051
Echocardiography
LVEF, % 50.9+15.3 48.3+15.9 0.008
LVEF ≤50%, n (%) 465 (44.3) 182 (53.7) 0.003
Continued
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Furosemide equivalent dose and all-cause
mortality across serum carbohydrate
antigen 125–estimated glomerular
filtration rate categories
In a sensitivity analysis, a composite variable (CA125–eGFR) with
four categories was created, with eGFR dichotomized at 45
mL/min/m2, and CA125 at 35 U/mL. The multivariable model for
all-cause mortality that included CA125–eGFR had the same set
of covariates as the CA125–BUN model. The P-value for the inter-
action was significant (P ¼ 0.001). This sensitivity analysis con-
firmed the presence of a differential effect of HDLD on
mortality, with estimates pointing to the same direction as in the
CA125–BUN model (Table 3). It is worth mentioning that the
effect of HDLDs in C4 was not significant (P ¼ 0.135); moreover,
the discriminative accuracy of using eGFR instead of BUN
decreased (Harrell’s C-statistics ¼ 0.741 vs. 0.770) (Table 3).
Discussion
The principal finding of this hypothesis-generating study is that the
mortality risk associated with the prescription of HDLDs at dis-
charge is differentially dependent on CA125 and BUN serum
values. Loop diuretics are viewed as a double-edged sword; on
the one hand, they are very effective in relieving symptoms of
systemic and pulmonary congestion in patients with AHF; on the
other hand, their use, particularly in high doses, has been asso-
ciated with increased mortality.3–6 In the absence of well-designed
randomized studies, it has been very difficult to determine if the
associated increased risk in mortality merely represents a spurious
association due to confounding by indication, as has been suggested
by recent findings.24,25 or a real effect. In reference to this topic,
direct roles, by promoting renal dysfunction and stimulating multiple
neurohormonal systems [including the renin–angiotensin–aldoster-
one system (RAAS) activity], have been proposed as crucial factors
explaining the diuretic-associated detrimental effects.25–28 A recent
study showed in a selected cohort of 2456 compensated HF patients
with LVEF ≤ 35% that high BUN (.21 mg/dL) identified those with
an increased risk of mortality when HDLDs ( ≥ 160 mg/day) were
prescribed.9 Given that urea tubular reabsorption is largely depend-
ent on neurohormonal activation,29,30 these authors proposed that
an elevated BUN level, in addition to being a marker related to re-
duction of glomerular filtration, may act as surrogate for RAAS ac-
tivity.7–9,30
In other respects, it is also known that diuretics sometimes
improve renal function,26,27 and recent studies have highlighted
the role of venous congestion rather than reduced arterial renal
perfusion in the pathophysiology of renal function impairment
observed in HF.10–13 For instance, recent works have shown
that elevated intra-abdominal and central venous pressure, but
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Table 2 Continued
Variables Furosemide equivalent dose <120 mg/day
(n5 1050)
Furosemide equivalent dose ≥120 mg/day
(n 5 339)
P-value
LAD, mm 42.5+7.2 45.1+9 ,0.001
LVDD, mm 55.1+9.5 57.5+10.1 ,0.001
Medical treatment
Beta-blockers, n (%) 621 (59.1) 175 (51.6) 0.016
Diuretics, n (%) 1050 (100.0) 339 (100.0) 1.00
Furosemide equivalent dose, mg/daya 60 (40–80) 120 (120–120) ,0.001
Mineralcorticoid receptor inhibitors,
n (%)
223 (21.2) 99 (29.2) 0.003
ACEI, n (%) 426 (40.6) 121 (35.7) 0.125
ARB, n (%) 334 (31.8) 100 (29.5) 0.459
Oral anticoagulants, n (%) 430 (41) 133 (39.2) 0.611
Nitrates, n (%) 179 (17) 84 (24.8) 0.002
Digoxin, n (%) 254 (24.2) 90 (26.5) 0.386
Outcomes
All-cause mortality, n (%) 352 (33.5) 209 (61.7) ,0.001
Cardiovascular mortality, n (%) 259 (24.7) 145 (42.8) ,0.001
Follow-up time, yearsa 1.8 (0.7–3.6) 1.5 (0.5–3.5) 0.048
Values are expressed as mean+ standard deviation, unless otherwise specified; categorical variables are presented as percentages.
ACEI, angiotensin-converting enzyme inhibitor; ADHF, acute decompensated heart failure; AHF, acute heart failure; ARB, angiotensin II receptor blocker; BNP, brain natriuretic
peptide; BUN, blood urea nitrogen; CA125, carbohydrate antigen 125; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HF, heart failure; LAD, left
atrial diameter; LVDD, left ventricular diastolic diameter; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD, peripheral artery disease; SBP, systolic blood
pressure.
aValue presented as the median (interquartile range).
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not cardiac index, were related to the degree of impairment in
glomerular filtration.10–12 Along this line, Damman et al. showed
in 30 patients with stable chronic HF that following a diuretic with-
drawal, a subtle urinary volume increase occurred, paralleling an in-
crease in markers of tubular renal injury.13 CA125, a glycoprotein
released by mesothelial cells in response to a mechanical or inflam-
matory stimulus, has been shown to be a reliable marker of sys-
temic congestion.15218 In fact, serum levels of this glycoprotein
were significantly related to the presence of mesothelial effusion
and peripheral oedema, independent of age, gender, and renal
function.17 Interestingly, CA125 provided additional prognostic in-
formation beyond natriuretic peptides.17 In addition, other factors
such as wide availability, low cost, standardized measurement, and
long half-life support the use of this biomarker in routine clinical
practice.16–18
In this study, conciliating both previous pathophysiological pos-
tulates, we found that the high mortality risk associated with the
use of HDLDs is strongly dependent on levels of BUN and
serum CA125. We found that in patients with CA125 ,35 U/mL
(no important fluid overload), HDLDs were associated with high
mortality in patients with BUN above the median (C1), but not
in those with BUN below the median (C2), reproducing the
results recently published by Testani et al.9 in patients with
stable chronic HF, a scenario where the majority of patients
exhibit normal CA125 values.18 Thus, in the absence of important
fluid overload, higher BUN levels may help to identify those
patients in which the potentially beneficial effect of HDLD does
not produce the potentially deleterious effect on renal function
and/or neurohormonal activation.
Conversely, in patients with CA125 ≥ 35 U/mL, the direction of
the association mediated by BUN levels was divergent. Indeed, the
use of HDLDs in patients with high BUN (C4) was associated with
improved survival, while in those with low BUN it was associated
with higher mortality (C3). Based on previous experimental studies
where selective congestion of the renal veins induced an increase
in neurohormonal parameters,31,32 we speculate that the survival
benefit associated with the use of HDLD suggests that renal dys-
function/neurohormonal activation largely depends on venous
Figure 1 Adjusted hazard ratios (and their 95% pointwise confidence intervals) for the effect of FED on mortality at each BUN–CA125
category. FED is modelled with df(4) RCS. Hazard ratios are calculated against the value of 40 mg/day as reference point. BUN, blood urea
nitrogen; CA125, carbohydrate antigen 125; CI, confidence interval; FED, furosemide equivalent dose; HR, hazard ratio; RCS, restricted
cubic splines.
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congestion in C4 patients, a situation where an aggressive decon-
gestion would result in a net positive prognostic effect.
Finally, CA125 .35 U/mL and BUN below the median (C3) may
help to identify those patients with fluid overload or tissue redis-
tribution where renal venous congestion is not important, a situ-
ation where an adequate diuretic response would be expected
following the first weeks after hospitalization. Based on a previous
result showing that CA125 undergoes important modifications fol-
lowing the first weeks after discharge (especially for those with
high values during hospitalization),18 we speculate that the
excess risk associated with the use of HDLDs in this category
(high CA125 in the absence of renal dysfunction/neurohormonal
activation) stems from the fact that most of these patients would
control fluid overload within the first weeks following discharge
(normalizing CA125 values) and, therefore, move either to C2
(normal CA125 and BUN) or to C1 (normal CA125 but elevated
BUN).
Our findings underscore the importance of including a surrogate
for systemic/pulmonary congestion as part of the equation relating
HDLDs to mortality. Indeed, we believe that this hypothesis-
generating study constitutes a first step to delineate further clinical
research lines in order to: (i) select those patients who benefit
from the use of HDLDs; and (ii) carefully titrate the intensity of di-
uretic therapy for those patients deemed at risk for their deleteri-
ous effects. A clinical instrument able to perform these two tasks
represents an unmet need in the management of patients dis-
charged after an episode of AHF, a situation where a residual
fluid overload may still be present.14
Limitations
Given the observational nature of this study, the contamination of
our results due to confounding by indication cannot be excluded.
Furthermore, the fact that the treating physicians were not blinded
to the value of these markers makes this study prone to channel-
ling bias, even in the absence of specific recommendations about
the use of CA125 and BUN for guiding patient therapy. In order
to minimize such unintentional influences, and within the available
resources, we developed a well-adjusted multivariable model by in-
cluding the most important predictors of mortality in AHF using a
state of the art survival methodology.21 Is also worth mentioning
the possibility that the sample size may have been insufficient to
test the interaction effects with appropriate statistical power.
We have assumed throughout the study that CA125 is a reliable
surrogate for fluid overload, and also renal venous congestion, a
presumption that needs to be corroborated with carefully
designed experimental studies. BUN values are influenced by
prior administration of HDLDs and other factors such as protein
catabolism and diet, factors that were not accounted for in this
study and might act as important confounders. Furthermore, the
lack of serial measurements and the temporal dissociation
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Table 3 Multivariable regression estimates indicating the effect of high-dose loop diuretics on all-cause and
cardiovascular mortality, according to carbohydrate antigen 125–blood urea nitrogen, carbohydrate antigen
125–creatinine, and carbohydrate antigen 125–estimated glomerular filtration rate categories
Dual-marker variables Hazard ratio (95% CIs) P-value Harrell C-statistic Omnibus P-value
All-cause mortality
CA125 categories–BUN categoriesa HDLDs
C1 2.29 (1.51–3.46) 0.000 0.770 ,0.001
C2 1.22 (0.73–2.04) 0.448
C3 1.94 (1.36–2.76) 0.000
C4 0.73 (0.55–0.98) 0.034
CA125–eGFRb HDLDs
C1 2.41 (1.40–4.14) 0.002 0.741 ,0.001
C2 1.67 (1.12–2.48) 0.011
C3 1.46 (1.11–1.92) 0.007
C4 0.76 (0.54–1.09) 0.135
CV mortality
CA125 categories–BUN categoriesa HDLDs
C1 2.42 (1.54–3.78) 0.000 0.7535 0.003
C2 0.95 (0.51–1.75) 0.861
C3 1.21 (0.75–1.95) 0.432
C4 0.86 (0.61–1.20) 0.366
BUN, blood urea nitrogen; CA125, serum carbohydrate antigen 125; eGFR, estimated glomerular filtration rate; HDLD, high-dose loop diuretics (furosemide equivalent doses
≥120 mg/day).
aCA125 and BUN categories: C1, CA125 ≤35 U/mL and BUN above the median; C2, CA125 ≤35 U/mL and BUN below the median; C3, CA125 .35 U/mL and BUN below the
median; C4, CA125 .35 U/mL and BUN above the median.
bCA125 and eGFR: C1, CA125 ≤35 U/mL and eGFR ,45 mL/min/m2; C2, CA125 ≤35 U/mL and eGFR ≥ 45 mL/min/m2; C3, CA125 .35 U/mL and eGFR ≥45 mL/min/m2;
C4, CA125 .35 U/mL and eGFR ,45 mL/min/m2.
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between the variables precludes evaluating the updated effect of
FED, BUN, and CA125 on mortality. Finally, we cannot unravel
the complex mechanisms underlying these results.
Conclusions
Following a hospital discharge for AHF, the higher mortality risk
associated with the use of HDLDs appears to be dependent on
levels of CA125 and BUN. In patients with normal CA125,
HDLD use was associated with higher mortality if BUN was
above the median but not in those where it was below the
median. Conversely, in patients with high CA125, the direction
of the association mediated by BUN levels was the opposite (the
HDLD group showed an association with increased survival if
BUN was above the median, but an association with increased
mortality in those with BUN below the median). Further studies
are needed to corroborate our results and to provide robust ex-
perimental evidence about the complex association between
HDLD dose, renal function, systemic congestion, neurohormonal
activation, and subsequent mortality.
Supplementary material
Supplementary material is available at European Journal of Heart
Failure online.
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